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Objectives The objective of this study was to compare the predictive performance of bleeding risk–estimation tools in a
cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
Background Three bleeding risk–prediction schemes have been derived for and validated in patients with AF:
HEMORR2HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or
Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall Risk and Stroke), ATRIA (Anticoag-
ulation and Risk Factors in Atrial Fibrillation), and HAS-BLED (Hypertension, Abnormal Renal/Liver Function,
Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol). he
relative predictive values of these bleeding scores have not previously been compared.
Methods We analyzed the dataset from the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Aceno-
coumarol in Patients With Atrial Fibrillation) trial, a multicenter, randomized, open-label noninferiority study that
compared fixed-dose idraparinux with adjustable-dose oral vitamin K antagonist therapy in patients with AF. The
principal safety outcome was any clinically relevant bleeding event, which was a composite of major bleeding
plus clinically relevant nonmajor bleeding.
Results The HAS-BLED score performed best in predicting any clinically relevant bleeding, reflected both in net reclassifi-
cation improvement (10.3% and 13% improvement compared with HEMORR2HAGES and ATRIA, respectively)
and receiver-operating characteristic (ROC) analyses (c-indexes: 0.60 vs. 0.55 and 0.50 for HAS-BLED vs.
HEMORR2AGES and ATRIA, respectively). Using decision-curve analysis, the HAS-BLED score demonstrated supe-
rior performance compared with ATRIA and HEMORR2HAGES at any threshold probability for clinically relevant
bleeding. HAS-BLED was the only score that demonstrated a significant predictive performance for intracranial
hemorrhage (c-index: 0.75; p  0.03). An ATRIA score 3 was not significantly associated with the risk for any
clinically relevant bleeding on Cox regression or on ROC analysis (c-index: 0.50; p  0.87).
Conclusions All 3 tested bleeding risk–prediction scores demonstrated only modest performance in predicting any clinically relevant
bleeding, although the HAS-BLED score performed better than the HEMORR2HAGES and ATRIA scores, as reflected by ROC
analysis, reclassification analysis, and decision-curve analysis. Only HAS-BLED demonstrated a significant predictive perfor-
mance for intracranial hemorrhage. Given its simplicity, the HAS-BLED score may be an attractive method for the estima-
tion of oral anticoagulant–related bleeding risk for use in clinical practice, supporting recommendations in international
guidelines. (J Am Coll Cardiol 2012;60:861–7) © 2012 by the American College of Cardiology Foundation
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CrCl  creatinine clearance; NSAID  nonsteroidal anti-inflammatory drug; SBP  systolic blood
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HEMORR2HAGES, ATRIA, and HAS-BLED in AF August 28, 2012:861–7Although various bleeding risk–
prediction tools have been de-
rived in general populations un-
dergoing anticoagulation, only 3
schemes have been initially derived
for and validated exclusively in pa-
tients with atrial fibrillation (AF):
HEMORR2HAGES (Hepatic or
Renal Disease, Ethanol Abuse,
Malignancy, Older Age, Reduced
Platelet Count or Function, Re-
Bleeding, Hypertension, Anemia,
Genetic Factors, Excessive Fall Risk
and Stroke) (1); HAS-BLED (Hy-
pertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History
or Predisposition, Labile Interna-
tional Normalized Ratio, Elderly,
Drugs/Alcohol) (2); and ATRIA
(Anticoagulation and Risk Factors
in Atrial Fibrillation) (3).
In the present study, the rela-
tive predictive values of these 3
tools used for AF bleeding risk
assessment were compared in a
ost hoc analysis of data from warfarin-treated patients in
he AMADEUS (Evaluating the Use of SR34006 Com-
ared to Warfarin or Acenocoumarol in Patients With Atrial
ibrillation) trial. We tested the hypothesis that HAS-BLED
ould perform at least as well as the (older, more complex)
EMORR2HAGES and new (weighted) ATRIA tools in
predicting the principal trial safety outcome of clinically
relevant bleeding events. Secondary objectives included
testing these schemes for the endpoints of major bleeding
only and death.
Patients and Methods
Study population. The study design of AMADEUS has
been previously described (4). A detailed description of the
study design is provided in the Online Appendix.
Calculation of bleeding risk scores. Bleeding risk scores
in each patient were estimated on the basis of the definitions
used in their validation cohorts (Online Table 1), with the
following limitations: 1) in the absence of relative data,
genetic factors associated with an increased risk for bleeding
were not used in the calculation of the HEMORR2HAGES
score; 2) none of the patients had a history of active
malignancy, alcohol abuse, or major bleeding at study entry,
as these were criteria for exclusion from the trial; and 3) in
the absence of data on prior international normalized ratio
(INR) control, we used each patient’s first 5 INR measure-
ments following study entry to calculate time in therapeutic
range.
Study endpoints. We used data only from the vitamin K
Abbreviations
and Acronyms
AF  atrial fibrillation
ATRIA  Anticoagulation
and Risk Factors in Atrial
Fibrillation
DCA  decision-curve
analysis
HAS-BLED  Hypertension,
Abnormal Renal/Liver
Function, Stroke, Bleeding
History or Predisposition,
Labile International
Normalized Ratio, Elderly,
Drugs/Alcohol
HEMORR2HAGES 
Hepatic or Renal Disease,
Ethanol Abuse, Malignancy,
Older Age, Reduced
Platelet Count or Function,
Re-Bleeding, Hypertension,
Anemia, Genetic Factors,
Excessive Fall Risk and
Stroke
ROC  receiver-operating
characteristicantagonist arm and included events that occurred both in the pThe AMADEUS Patients Randomized toVKA Stratified by Presence or Abs nce ofBl eding Ev nts Duri g th On-Treatm nt andObservational Study P riod
Table 1
The AMADEUS Patients Randomized to
VKA Stratified by Presence or Absence of
Bleeding Events During the On-Treatment and
Observational Study Period
Characteristic
No Bleeding
Events
(n  2,041)
Any Clinically
Relevant
Bleeding
(n  251) p Value
Demographics
Age, yrs 70 9 71 8 0.40
Age 75 yrs 737 (36.1) 87 (34.7) 0.68
Age 65 to 75 yrs 705 (34.5) 101 (40.2) 0.08
Male 1,328 (65.1) 173 (68.9) 0.23
Disease history
Hypertension (diagnosed) 1,575 (77.2) 189 (75.3) 0.53
Uncontrolled hypertension
(SBP 160 mm Hg)
273 (13.4) 37 (14.7) 0.56
Diabetes mellitus 394 (19.3) 56 (22.3) 0.27
Previous stroke 270 (13.2) 39 (15.5) 0.33
Previous TIA 229 (11.2) 27 (10.8) 0.92
Coronary artery disease 618 (30.3) 100 (39.8) 0.002
Laboratory analysis
Left ventricular dysfunction 482 (23.6) 61 (24.3) 0.81
Renal impairment
(CrCl 30 ml/min)
6 (0.3) 1 (0.4) 0.55
Liver impairment* 27 (1.3) 4 (1.6) 0.77
Reduced platelet count† 3 (0.1) 3 (1.2) 0.02
Anemia‡ 221 (10.9) 29 (11.6) 0.75
Concurrent treatment
Antiplatelet 365 (17.9) 71 (28.3) 0.0001
NSAID 277 (13.6) 51 (20.3) 0.005
TTR
Mean  SD 58 20 0.53 0.2 0.0001
Patients with TTR 60% 1,036 (50.8) 159 (63.3) 0.0001
CHADS2 score§ 2.1 1.2 2.1 1.2 0.59
Patients with each score 0.69
0 47 (2.3) 7 (2.8)
1 740 (36.2) 84 (33.5)
2 635 (31.1) 81 (32.3)
3 357 (17.5) 46 (18.3)
4 199 (9.7) 22 (8.8)
5 57 (2.8) 11 (4.4)
6 7 (0.3) 0
CHA2DS2VASc score 3.5 1.5 3.6 1.5 0.12
Patients with each score 0.79
0 0 0
1 163 (8) 16 (6.4)
2 435 (21.3) 46 (18.3)
3 505 (24.7) 62 (24.7)
4 442 (21.6) 59 (23.5)
5 281 (13.8) 40 (15.9)
6 144 (7.1) 16 (6.4)
7 59 (2.9) 9 (3.6)
8 12 (0.6) 3 (1.2)
9 1 (0.1) 0
Values are mean SD or n (%). *Defined as2-fold increase of alanine aminotransferase and/or
aspartate transaminase. †Defined as 75,000 platelets. ‡Defined as hemoglobin 13 g/dl in
men and 12 g/dl in women. §CHADS2, congestive heart failure, hypertension, age 75 years,
iabetes (1 point for each); stroke (2 points). CHA2DS2VASc, congestive heart failure, hyperten-
sion, age 75 years, diabetes, stroke, vascular disease, age 65 to 75 years, sex category
(female) (1 point each; 2 points for age 75 years and previous stroke).ressure; TIA transient ischemic attack; TTR time in therapeutic range; VKA vitamin K antagonist.
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August 28, 2012:861–7 HEMORR2HAGES, ATRIA, and HAS-BLED in AFrandomization/on treatment period and in the observational
period, which followed for a follow-up of 429 118 days. The
principal safety outcome of the trial was any clinically relevant
bleeding event, subclassified as major bleeding and clinically
AMADEUS Cohort Stratified by theHEMORR2HAGES, HAS-BLED, and ATRIA SchemesTable 2 AMADEU Cohort Stratified by theHEMORR2HAGES, HAS-BLED, and ATRIA Schemes
Scheme All Patients
Clinically Relevant
Bleeding Major Bleeding
HEMORR2HAGES
0 777 (34.3) 64 (8.2) 8 (1)
1 961 (42.4) 118 (12.3) 17 (1.8)
2 432 (19) 50 (11.6) 9 (2.1)
3 85 (3.7) 13 (15.3) 4 (4.7)
4 13 (0.5) 3 (23.1) 1 (7.6)
Risk
Low (1) 1,738 (76.6) 182 (10.5) 25 (1.4)
Intermediate (2–3) 517 (22.8) 63 (12.2) 13 (2.5)
High (3) 13 (0.5) 3 (23.1) 1 (7.7)
Total 2268 248 (10.9) 39 (1.7)
HAS-BLED
0 179 (7.8) 12 (6.7) 2 (1.1)
1 689 (30.1) 55 (8) 4 (0.6)
2 871 (38) 92 (10.6) 16 (1.8)
3 451 (19.7) 74(16.4) 13 (2.9)
4 89 (3.9) 13 (14.6) 3 (3.4)
5 13 (0.6) 5 (38.5) 1 (7.7)
Risk
Low (3) 1,739 (75.9) 159 (9.1) 22 (1.3)
High (3) 553 (24.1) 92 (16.6) 17 (3.1)
Total 2,292 251 (11.0) 39 (1.7)
ATRIA
0 258 (11.4) 30 (11.6) 3 (1.2)
1 1,066 (47) 116 (10.9) 13 (1.2)
2 211 (9.3) 24 (11.4) 4 (1.9)
3 503 (22.2) 50 (9.9) 11 (2.2)
4 102 (4.5) 13 (12.7) 3 (2.9)
5 28 (1.2) 5 (17.9) 1 (3.6)
6 99 (4.3) 10 (10.1) 4 (4)
7 1 (0.1) 0 (0) 0 (0)
Risk
Low (4) 2,038 (90) 220 (10.8) 31 (1.5)
Intermediate (4) 102 (4.4) 13 (12.7) 3 (2.9)
High (4) 128 (5.6) 18 (14.1) 5 (3.9)
Total 2,268 248 (10.9) 39 (1.7)
Values are n (%).
ATRIA  Anticoagulation and Risk Factors in Atrial Fibrillation; HAS-BLED  Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International
Normalized Ratio, Elderly, Drugs/Alcohol; HEMORR2HAGES  Hepatic or Renal Disease, Ethanol
buse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension,
nemia, Genetic Factors, Excessive Fall Risk and Stroke.
AUCs (or C-Indexes) for HEMORR2HAGES, ATRIA, and HAS-BLED STable 3 AUCs (or C-Indexes) for HEMORR2HAGES, ATRIA, and
AUC Analysis
Any Clinically Relevant Bleeding
AUC 95% CI SE AUC
HEMORR2HAGES 0.55 0.51–0.59 0.019 0.60
HAS-BLED 0.60 0.56–0.63 0.019 0.65
ATRIA 0.50 0.46–0.54 0.020 0.61AUC  area under the curve; CI  confidence interval; SE  standard error; other abbreviations as in Tabrelevant nonmajor bleeding. Definitions of the study endpoints
are provided in the Online Appendix.
Statistical analysis. The prognostic value of each score was
determined using Cox proportional hazards analysis.
C-indexes were calculated for each of the study endpoints.
Net reclassification improvement and decision-curve analy-
sis (DCA) were used to quantify the clinical usefulness of
the prediction models. Further details on the statistical
methods are provided in the Online Appendix.
Results
The AMADEUS study randomized 2,293 patients to the
vitamin K antagonist arm (65% men; mean age: 70.2  9.1
years). In total, 251 (11%) patients experienced at least 1
clinically relevant bleeding event. Thirty-nine (1.7%) pa-
tients had at least 1 episode of major bleeding. The
demographic and clinical characteristics of the AMADEUS
population are summarized in Table 1. The bleeding event
rates in the study population, stratified by the three bleeding
estimation schemas, are summarized in Table 2.
The HEMORR2HAGES bleeding scheme. Median
score in the cohort was 1 (interquartile range: 0 to 1). The
predictive performance of HEMORR2HAGES for both
the study bleeding outcomes was modest, as reflected by
c-index of 0.55 and 0.60, for clinically relevant bleeding and
major bleeding, respectively (Table 3, Fig. 1). In a Cox
regression analysis, a HEMORR2HAGES score 1 was
associated with a significantly higher risk of all cause
mortality but this score was not associated with bleeding—
regardless of whether defined as major or clinically relevant
bleeding (Table 4, Online Fig. 1).
The HAS-BLED bleeding scheme. The median HAS-
BLED score in the cohort was 2 (interquartile range: 1 to
2). The predictive performance of HAS-BLED for both the
study bleeding outcomes was modest, as reflected by c-index
of 0.60 and 0.65, for clinically relevant bleeding and major
bleeding, respectively (Table 3, Fig. 1). In a Cox regression
analysis, a HAS-BLED score2 was associated with an 85%
higher risk for any clinically relevant bleeding and a 2.4-fold
higher risk for major bleeding (Table 4, Online Fig. 1). A
HAS-BLED score 2 was also associated with 2.9 fold
greater risk of death during the study period (Table 4).
The ATRIA bleeding scheme. The median ATRIA score
in the cohort was 1 (interquartile range: 1 to 3). The
predictive performance of the ATRIA schema as reflected
by the c-index were 0.50 and 0.61, for clinically relevant
BLED Scores
Major Bleeding Death
95% CI SE AUC 95%CI SE
0.51–0.69 0.046 0.57 0.50–0.65 0.033
0.56–0.73 0.043 0.67 0.60–0.73 0.035
0.51–0.70 0.048 0.63 0.56–0.69 0.037coresHAS-le 2.
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HEMORR2HAGES, ATRIA, and HAS-BLED in AF August 28, 2012:861–7bleeding and major bleeding, respectively (Table 3, Fig. 1).
On Cox regression analysis, an ATRIA score 3 was not
significantly associated with the risk of any clinically rele-
vant bleeding. An ATRIA score 3 was associated with a
significantly higher risk of all-cause mortality and major
bleeding (Table 4, Online Fig. 1).
Comparison of bleeding schemas. The Hosmer-Lemeshow
goodness-of-fit statistics supported model fit of all risk-
stimation tools for both bleeding outcomes and all-cause
ortality, as indicated by p values 0.05.
There were substantial differences among the 3
chemes with respect to the definition of low and
ntermediate/high bleeding risk. HEMORR2HAGES,
HAS-BLED, and ATRIA categorized 1,738 (76.6%),
1,739 (75.9%), and 2,038 (90%) patients, respectively, as
low bleeding risk.
Cohen’s kappa coefficient revealed poor concordance
between ATRIA and the other 2 schemas (kappa: 0.2)
and moderate concordance among HAS-BLED and
HEMORR2HAGES (kappa: 0.46). Only 56 (2.7%) pa-
Figure 1 Receiver-Operating Characteristic Curves of the Bleed
The HAS-BLED score performed better for the primary endpoint of any clinically rel
ATRIA (0.6 vs. 0.5; p  0.002). Further details in c-indexes comparisons are avail
HAS-BLED  Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding Histo
HEMORR2HAGES  Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older A
Factors, Excessive Fall Risk and Stroke.
Cox Regression Analysis of the HEMORR2HAGES, HAS-BLED, and Afor the Outcomes of All-Cause Mortality, Major Bleeding, and A y CTable 4 Cox Regressi n Analysis of the HEMORR2HAGES, HASfor the Outcomes of All-Cause Mortality, Major Bleedin
Score
Any Clinically Relevant Bleeding
HR (95% CI) p Value
HEMORR2HAGES 1 1.2 (0.9–1.5) 0.30
HAS-BLED 2 1.9 (1.4–2.4) 0.001
ATRIA 3 1.2 (0.8–1.7) 0.50HR  hazard ratio; other abbreviations as in Table 2.tients were classified as intermediate/high risk by all 3
scores. Bleeding rates in the latter group were 5.4% and
16.1% for major bleeding and any clinically relevant bleed-
ing, respectively, and the mortality rate was 14.3%.
The HAS-BLED score performed best in predicting any
clinically relevant bleeding, reflected both on receiver-
operating characteristic (ROC) analyses (Table 5) and on
net reclassification improvement (Tables 6 and 7), as well as
n Cox regression analysis (Table 4). On ROC analysis, the
TRIA score failed to demonstrate a significant predictive
alue for clinically relevant bleeding (c-index: 0.50; p  0.87).
Using DCA, assuming that a classification of high risk by
ne of the tests will result in alternative treatment, HAS-
LED was superior to the “treat all alternatively” strategy
or a threshold probability of any clinically relevant bleeding
f 9% or more (Fig. 2). The HAS-BLED score was superior
o the HEMORR2HAGES and ATRIA scores for any
threshold probability.
HAS-BLED performed better in predicting major
bleeding events, as reflected by the slightly greater
isk Schemes for the 3 Outcomes
bleeding compared with HEMORR2HAGES (c-index: 0.6 vs. 0.55; p  0.003) and
Tables 3 and 5. ATRIA  Anticoagulation and Risk Factors in Atrial Fibrillation;
redisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol;
duced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic
Scoreal Rel vant Bleeding, and ATRIA Score
d Any Clinical Relevant Bleeding
Major Bleeding All-Cause Mortality
(95% CI) p Value HR (95% CI) p Value
(0.9–3.5) 0.08 2.0 (1.3–3.3) 0.003
(1.3–4.6) 0.006 2.9 (1.9–4.6) 0.001
(1.1–5.1) 0.03 2.3 (1.3–4.0) 0.005ing R
evant
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August 28, 2012:861–7 HEMORR2HAGES, ATRIA, and HAS-BLED in AFc-index, although differences in c-index and net reclassi-
fication improvement did not reach statistical significance
compared with the other 2 scores (Fig. 1). With respect to
all-cause mortality, HAS-BLED performed better than
HEMORR2HAGES, as reflected by both c-index and net
reclassification improvement, but the difference between HAS-
BLED and ATRIA did not reach statistical significance.
With respect to bleeding subtypes, HEMORR2HAGES
and ATRIA scores did not demonstrate any significant
predictive performance when fatal bleeding or intracranial
hemorrhage was assessed independently (all, p  NS; full
data not shown). HAS-BLED was the only score that
demonstrated a significant predictive performance for intra-
cranial hemorrhage (c-index: 0.75; 95% CI: 0.56 to 0.95;
p  0.03).
Discussion
In this study, we compared, for the first time, the
HEMORR2HAGES, HAS-BLED, and ATRIA scores, in
predicting bleeding events in a clinical trial cohort under-
going anticoagulation. We demonstrated a clear advantage
of the HAS-BLED score over both the ATRIA and
HEMORR2HAGES scores. Also, HAS-BLED was the
only score to demonstrate a significant predictive perfor-
mance for intracranial hemorrhage. An ATRIA score 3
Comparison of AUCs or C-Indexes for HEMORR2HAGES, ATRIA, andTable 5 Comparison of AUCs or C-Indexes for HEMORR2HAGES
Comparison
Any Clinically Relevant Bleeding
AUC Difference
(95% CI) z Score p Value
HAS-BLED vs. HEMORR2HAGES 0.04 (0.52 to 0.59) 2.95 0.003 0.0
HAS-BLED vs. ATRIA 0.09 (0.03 to 0.15) 3.14 0.002 0.0
ATRIA vs. HEMORR2HAGES 0.05 (0.01 to 0.11) 1.54 0.10 0
Abbreviations as in Tables 2 and 3.
Reclassification Table for Any Clinical RelevantEstimated by HAS-BLED, HEMORR2HAGES, dTable 6 Reclassificatio Table for Any Cli icEstimated by HAS-BLED, HEMORR2
High
ATRIA
High
Event 18
No Event 67
Low
Event 74
No Event 393
Total
Event 92
No Event 460
HEMORR2HAGES
High
Event 54
No Event 306
Low
Event 38
No Event 158
Total
Event 92
No Event 464Abbreviations as in Table 2.was not significantly associated with the risk for any
clinically relevant bleeding event on Cox regression or ROC
analysis.
This comparison is of practical importance because bleed-
ing risk–scoring systems are featured in management guide-
lines for stroke prevention in AF. The HAS-BLED scheme
is recommended by the European Society of Cardiology and
Canadian guidelines (5–7). The HAS-BLED score was also
highlighted in the recent Royal College of Physicians of
Edinburgh United Kingdom Consensus Conference on
Atrial Fibrillation (7).
In our analyses, the 3 bleeding scores exhibited weak
discriminatory capacity for both bleeding outcomes, as
reflected by c-indexes below 0.70. Bleeding risk estimation
has always been challenging and far more complicated than
thromboembolic risk estimation. Even in validation cohorts
(1–3), none of the bleeding risk–estimation tools exceeded
a c-index of 0.74 despite the numerous risk factors incor-
porated for their calculation (13 for HEMORR2HAGES, 8
or HAS-BLED, and 5 for ATRIA). However, the c-index
s not the only parameter to be taken into consideration in
etermining the utility or predictive ability of risk-
stimation schemas (8). From the clinical perspective, re-
lassification analysis seems to be of greater importance,
specially for patients reclassified correctly from low-
-BLED ScoresIA, and HAS-BLED Scores
Major Bleeding Death
ifference
% CI) z Score p Value
AUC Difference
(95% CI) z Score p Value
.03 to 0.12) 1.19 0.23 0.09 (0.14 to0.05) 4.33 0.0001
.06 to 0.14) 0.85 0.40 0.04 (0.03 to 0.11) 1.17 0.20
.09 to 0.09) 0.04 0.97 0.05 (0.12 to 0.02) 1.50 0.10
ding RiskA Schemaselevant Bleeding Risk
S, and ATRIA Schemas
AS-BLED HEMORR2HAGES
Low Total High Low Total
10 28 10 18 28
135 202 83 119 202
146 220 56 164 220
1,425 1,818 381 1,437 1,818
156 248 66 182 248
1,560 2,020 464 1,556 2,020
12 66
154 460
144 182
1,402 1,560
156 248
1,556 2,020HAS, ATR
AUC D
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HEMORR2HAGES, ATRIA, and HAS-BLED in AF August 28, 2012:861–7intermediate risk to high risk, as these patients will be
considered for alternative treatment.
With respect to the principal outcome of any clinically
relevant bleeding, the ATRIA score failed to demonstrate
any additional predictive value over chance alone, whereas
HEMORR2HAGES was slightly better than random strat-
ification. HAS-BLED was significantly better than the
other 2 scores in predicting any clinically relevant bleeding.
Using DCA, the HAS-BLED score performance was
superior to that of HEMORR2HAGES and ATRIA with
espect to its clinical applicability for whole-spectrum
hreshold probabilities.
The fact that HAS-BLED exhibited predictive capacity
or clinically relevant bleeding should be considered as an
dvantage, especially because nonmajor clinically relevant
leeding may significantly influence outcome by interrupt-
ng or affecting the quality of anticoagulation. Also, only
AS-BLED had a significant (and “good,” c-index: 0.75)
Figure 2
Decision Curve Analysis: Net Number of True
Positives Gained Using a Model Compared to
No Model at a Range of Thresholds Probabilities
We assume that a classification of high risk on one of the tests will result in
alternative treatment. If it is considered efficient to apply alternative treatment
in 11 patients or less to prevent 1 clinically relevant bleeding event (i.e.,
threshold probability 9%; dotted arrow), then HAS-BLED is superior to the
“treat all alternatively” strategy (gray line) and the “treat none alternatively”
strategy (black dotted line). The HAS-BLED score was also superior to the
HEMORR2HAGES and ATRIA scores for any threshold probability. For a thresh-
old probability of 9%, the “treat all alternatively” strategy provides the high-
est net clinical benefit. Abbreviations as in Figure 1.
NRI Analysis for the Outcomes of Any Clinically Relevant Bleeding,Table 7 NRI Analysis for the Outcomes of Any Clinically Releva
Comparison
Any Clinically Relevant Bleeding
NRI z Score p Value
HAS-BLED vs. HEMORR2HAGES 0.103 3.45 0.001
HAS-BLED vs. ATRIA 0.13 3.37 0.001
ATRIA vs. HEMORR2HAGES 0.021 0.596 0.55
NRI  net reclassification improvement; other abbreviations as in Table 2.redictive ability for intracranial hemorrhage, a potential
ffect of oral anticoagulation. With respect to major bleed-
ng events, all 3 scores demonstrated significant predictive
bility, although their c-indexes were below the cutoff point
f what is considered good performance (c-index: 0.70).
o statistically significant differences were observed be-
ween the 3 scores in the outcome of major bleeding.
ortality prediction. Bleeding risk–prediction schemes
ere not developed to predict mortality, although major
leeding and mortality are closely related endpoints in
opulations undergoing anticoagulation (9). In our analysis,
he HAS-BLED score performed best in predicting all-
ause mortality, as reflected by the c-index, followed by the
TRIA score. The HEMORR2HAGES score had the
orst performance, probably due to the larger number of
leeding-oriented factors that are used for its calculation.
tudy limitations. These are results of a post hoc analysis
nd they should be interpreted as such. The AMADEUS
rial population was at relatively low risk for both ischemic
troke and bleeding events compared with patients in
linical practice; patients with a history of major bleeding
vents or who are at risk for bleeding were excluded from
he study. It remains to be established whether these risk
cores would have a similar accuracy in clinical practice.
inally, this was a retrospective analysis, and no available
rials have evaluated prospectively the impact of the use of
hese 3 bleeding risk–estimation schemes on patient out-
omes (10).
onclusions
ll 3 tested bleeding risk–estimation scores demonstrated
nly modest performance in predicting the outcome of any
linically relevant bleeding, although the HAS-BLED score
erformed better than the HEMORR2HAGES and
TRIA scores, as reflected by ROC analysis, reclassification
nalysis, and DCA. Only HAS-BLED demonstrated a
ignificant predictive performance for intracranial hemor-
hage. Given its simplicity, the HAS-BLED score may be an
ttractive method for the estimation of oral anticoagulant–
elated bleeding risk for use in clinical practice, supporting the
ecommendations in the international guidelines.
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